ALNY Financials: Alnylam Pharmaceuticals Inc AI Analysis



Financials

ALNY Financial

Alnylam Pharmaceuticals Inc

$284.84

-3.46%

$-10.21

At close: May 11, 16:00:00 GMT-4

$284.09

-0.26%

$-0.75

Pre-market: May 12, 06:54:50 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$295.05

Open

$294.15

Day's Range

$284.09 - $296.37

52 week range

$250.35 - $495.55

Volume

1.2M

Avg.Volume

1.2M

Dividend yield

EPS (TTM)

4.18

Market Cap

$37.9B

What is ALNY?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	4,286	1,167	1,097	1,249	773	594
Revenue Growth (YoY)	83%	96%	85%	150%	17%	20%
Cost of Revenue	821	211	267	200	142	71
Gross Profit	3,464	956	829	1,048	630	523
Selling, General & Admin	1,293	322	325	322	323	239
Research & Development	1,419	364	372	358	323	265
Operating Expenses	2,755	687	697	680	646	505
Other Non Operating Income (Expenses)	-6	-4	-3	-9	10	10
Pretax Income	586	221	161	238	-35	-41
Income Tax Expense	9	15	-25	-12	30	15
Net Income	577	205	186	251	-66	-57
Net Income Growth	-315%	-459.99%	-324%	-326%	313%	-12%
Shares Outstanding (Diluted)	138.22	138.22	136.29	137.34	130.62	129.67
Shares Change (YoY)	7%	7%	6%	7%	3%	3%
EPS (Diluted)	4.17	1.51	1.36	1.82	-0.5	-0.44
EPS Growth	-299%	-441%	-311%	-311%	281%	-15%
Free Cash Flow	641	48	140	312	139	-127
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	80.82%	81.91%	75.56%	83.9%	81.5%	88.04%
Operating Margin	16.54%	22.96%	11.94%	29.38%	-2.06%	3.03%
Profit Margin	13.46%	17.56%	16.95%	20.09%	-8.53%	-9.59%
Free Cash Flow Margin	14.95%	4.11%	12.76%	24.97%	17.98%	-21.38%
EBITDA	763	281	144	380	-3	32
EBITDA Margin	17.8%	24.07%	13.12%	30.42%	-0.38%	5.38%
D&A For EBITDA	54	13	13	13	13	14
EBIT	709	268	131	367	-16	18
EBIT Margin	16.54%	22.96%	11.94%	29.38%	-2.06%	3.03%
Effective Tax Rate	1.53%	6.78%	-15.52%	-5.04%	-85.71%	-36.58%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

4,286

1,167

1,097

1,249

773

594

Revenue Growth (YoY)

83%

96%

85%

150%

17%

20%

Cost of Revenue

821

211

267

200

142

Gross Profit

3,464

956

829

1,048

630

523

Selling, General & Admin

1,293

322

325

322

323

239

Research & Development

1,419

364

372

358

323

265

Operating Expenses

2,755

687

697

680

646

505

Other Non Operating Income (Expenses)

-6

-4

-3

-9

Pretax Income

586

221

161

238

-35

-41

Income Tax Expense

-25

-12

Net Income

577

205

186

251

-66

-57

Net Income Growth

-315%

-459.99%

-324%

-326%

313%

-12%

Shares Outstanding (Diluted)

138.22

136.29

137.34

130.62

129.67

Shares Change (YoY)

EPS (Diluted)

4.17

1.51

1.36

1.82

-0.5

-0.44

EPS Growth

-299%

-441%

-311%

281%

-15%

Free Cash Flow

641

140

312

139

-127

Free Cash Flow Per Share

Gross Margin

80.82%

81.91%

75.56%

83.9%

81.5%

88.04%

Operating Margin

16.54%

22.96%

11.94%

29.38%

-2.06%

3.03%

Profit Margin

13.46%

17.56%

16.95%

20.09%

-8.53%

-9.59%

Free Cash Flow Margin

14.95%

4.11%

12.76%

24.97%

17.98%

-21.38%

EBITDA

763

281

144

380

-3

EBITDA Margin

17.8%

24.07%

13.12%

30.42%

-0.38%

5.38%

D&A For EBITDA

EBIT

709

268

131

367

-16

EBIT Margin

16.54%

22.96%

11.94%

29.38%

-2.06%

3.03%

Effective Tax Rate

1.53%

6.78%

-15.52%

-5.04%

-85.71%

-36.58%

Follow-Up Questions

What are Alnylam Pharmaceuticals Inc's key financial statements?



According to the latest financial statement (Form-10K), Alnylam Pharmaceuticals Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for ALNY?



Alnylam Pharmaceuticals Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Alnylam Pharmaceuticals Inc's revenue broken down by segment or geography?



Currently Alnylam Pharmaceuticals Inc data is not available.

Is Alnylam Pharmaceuticals Inc profitable?



no, according to the latest financial statements, Alnylam Pharmaceuticals Inc has a net loss of $0

Does Alnylam Pharmaceuticals Inc have any liabilities?



no, Alnylam Pharmaceuticals Inc has liability of 0

How many outstanding shares for Alnylam Pharmaceuticals Inc?



Alnylam Pharmaceuticals Inc has a total outstanding shares of 0

Alnylam Pharmaceuticals Inc (ALNY) Financial

ALNY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is ALNY?

Alnylam Pharmaceuticals Inc (ALNY) Financial

ALNY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is ALNY?

ALNY Income

Follow-Up Questions

What are Alnylam Pharmaceuticals Inc's key financial statements?

What are the key financial ratios for ALNY?

How is Alnylam Pharmaceuticals Inc's revenue broken down by segment or geography?

Is Alnylam Pharmaceuticals Inc profitable?

Does Alnylam Pharmaceuticals Inc have any liabilities?

How many outstanding shares for Alnylam Pharmaceuticals Inc?